ProNAi Reports Significant Activity and Ongoing Durable Responses in Relapsed or Refractory Non-Hodgkin's Lymphoma with PNT2258
Updated results from pilot Phase II trial of the BCL2 targeting DNAi® therapeutic reported at ASH 2014

December 5, 2014

Rugged Computer Keeps Running After It’s Dropped in an Aquarium

November 4, 2014

ProNAi Therapeutics Strengthens Senior Management Team to Advance DNAi®-based Oncology Therapeutics

October 22, 2014

OnKol Wants to Help Grandma Join the Internet of Things Movement

September 10, 2014

ProNAi Therapeutics, Inc. Names New President and Chief Executive Officer

September 3, 2014

ProNAi Therapeutics Raises $59.5 Million Series D Financing
Proceeds Will Advance Clinical Studies of Its BCL2 Targeted Cancer Drug and Other Pipeline Candidates

April 21, 2014

ProNAi Therapeutics Secures $12 Million Series C Financing to Expand Phase II Cancer Studies for PNT2258, a Novel BCL2 Inhibitor, in Defined Lymphoma Patients

January 13, 2014

LiquidCool Solutions Receives the 2013 North American Frost & Sullivan Customer Value Enhancement Award in Data Center Cooling

December 17, 2013

LiquidCool Solutions and Dedicated Computing Form Strategic Alliance to Develop Liquid Cooled Technical Computing Solutions

September 5, 2013

Great Lakes Pharmaceuticals, Inc. Announces Initiation of Clinical Study for the Antimicrobial Lock Solution, B-Lock™

July 24, 2012

CytoPherx Raises $34 Million to Move Into U.S. Clinical Trials
Early Stage Partners, Onset Ventures and Capital Midwest Fund Co-Lead Funding for Company Focused on Addressing Acute Kidney Injury

January 4, 2012

Sun Cofounder Evangelizes Liquid Blade Server

May 4, 2011

Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S.

April 23, 2010